AtriCure officer adds ESPP stock grant

Chief Scientific Officer Doraiswamy Vinayak acquired additional AtriCure, Inc. common stock through an employee purchase program.

Rhea-AI Filing Summary

Chief Scientific Officer Doraiswamy Vinayak acquired additional AtriCure, Inc. common stock through an employee purchase program. On June 30, 2026, he obtained 636 shares of Common Stock pursuant to the company’s 2018 Employee Stock Purchase Plan at $23.78 per share, a price based on 85% of the $27.98 closing price that day. Following this transaction, he directly holds 92,511 common shares, reflecting a small, routine compensation-related acquisition rather than an open-market trade.

Insider Trade Summary

Grant/Award: 636 shares

Grant/Award 1 txn

Insider Doraiswamy Vinayak

Role Chief Scientific Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	636	$23.78	$15K

Holdings After Transaction: Common Stock — 92,511 shares (Direct)

Footnotes (2)

1. F1. Shares acquired pursuant to the AtriCure, Inc. 2018 Employee Stock Purchase Plan for the period ended June 30, 2026.
2. F2. In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on June 30, 2026, which is the last trading day of the applicable offering period. The closing price on June 30, 2026, was $27.98.

Key Figures

Shares acquired: 636 shares Purchase price per share: $23.78 per share Reference closing price: $27.98 per share +2 more

5 metrics

Shares acquired 636 shares Common Stock acquired on June 30, 2026 via 2018 ESPP

Purchase price per share $23.78 per share ESPP acquisition price for AtriCure common stock

Reference closing price $27.98 per share Closing price on June 30, 2026 used for ESPP discount

Total holdings after transaction 92,511 shares Directly held AtriCure common stock following ESPP acquisition

ESPP discount rate 85% of closing price Plan formula applied to June 30, 2026 closing price

Key Terms

2018 Employee Stock Purchase Plan, closing price, grant/award acquisition, Common Stock

4 terms

2018 Employee Stock Purchase Plan financial

"Shares acquired pursuant to the AtriCure, Inc. 2018 Employee Stock Purchase Plan for the period ended June 30, 2026."

closing price financial

"These shares were purchased based on 85% of the closing price of the issuer's common stock on June 30, 2026."

grant/award acquisition financial

"Transaction code A is described as Grant, award, or other acquisition for this Form 4 entry."

Common Stock financial

"The reported security title for the transaction is Common Stock."

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did AtriCure (ATRC) report for Doraiswamy Vinayak?

AtriCure reported that Chief Scientific Officer Doraiswamy Vinayak acquired 636 shares of common stock. The shares were obtained through the company’s 2018 Employee Stock Purchase Plan, adding to his existing direct ownership position in AtriCure stock.

How many AtriCure (ATRC) shares does Doraiswamy Vinayak hold after this Form 4?

After the reported transaction, Chief Scientific Officer Doraiswamy Vinayak directly holds 92,511 shares of AtriCure common stock. This total includes the 636 shares acquired on June 30, 2026 through the employee stock purchase program.

At what price were the new AtriCure (ATRC) shares acquired under the ESPP?

The 636 shares of AtriCure common stock were acquired at $23.78 per share. According to the plan, this reflects 85% of the stock’s $27.98 closing price on June 30, 2026, the last trading day of the applicable offering period.

What is the AtriCure 2018 Employee Stock Purchase Plan mentioned in the Form 4?

The 2018 Employee Stock Purchase Plan allows eligible AtriCure employees to acquire common shares, typically at a discount. In this case, shares were purchased based on 85% of the $27.98 closing price on June 30, 2026, benefiting participating employees.

Is the Form 4 transaction for AtriCure (ATRC) an open-market stock purchase?

No, the Form 4 describes an acquisition under an Employee Stock Purchase Plan, not an open-market trade. The shares were acquired at a plan-defined price equal to 85% of the $27.98 closing price on June 30, 2026, as part of ongoing compensation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/02/2026 - 09:04 AM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Doraiswamy Vinayak

(Last) (First) (Middle)

7555 INNOVATION WAY

(Street)

MASON OHIO 45040-9695

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
AtriCure, Inc. [ ATRC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/30/2026		A		636(1)	A	$23.78(2)	92,511	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares acquired pursuant to the AtriCure, Inc. 2018 Employee Stock Purchase Plan for the period ended June 30, 2026.

2. In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on June 30, 2026, which is the last trading day of the applicable offering period. The closing price on June 30, 2026, was $27.98.

Remarks:

	/s/ Allison Walker as Attorney-in-fact for Vinayak S. Doraiswamy	07/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)